Nephropathy due to contrast agents. Postprocedural renal failure
Conditions
Interventions
Intervention 1: Intervention1: ampule N-acetyl cystein 1200 mg intravenously half an hour before contrast administration. Intervention 2: Intervention 2: Tablet N-acetyl cystein 600 mg bid, starting
Prevention
Placebo
Intervention1: ampule N-acetyl cystein 1200 mg intravenously half an hour before contrast administration
Intervention 2: Tablet N-acetyl cystein 600 mg bid, starting from the day before contrast administration and continued until the day after that.
Control1: intravenous saline 3 cc half an hour before contrast administration
Control2: Placebo tablet bid starting the day before contrast administration and continue until the day after that.
Sponsors
Nephrology Research Center, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age more than 18; serum creatinine more than 1.5 mg/ dl ; not having AKI; not receiving nephrotoxine since 1 week before entering the study; signing the consent. Exclusion criteria: the patients who undergo surgery in less than 1 week of contrast exposure; the patients who are in need for a nephrotoxine in less than five days after contrast exposure; the patients who need repeated contrast administration in less than five days of first exposure
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum creatinine. Timepoint: The second day and five days after contrast exposure. Method of measurement: Serum creatinine in plasma. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hypersensitivity to contrast. Timepoint: Immediately after exposure to contrast. Method of measurement: Physical conditions. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Reza Khatami
Nephrology Research Center
Outcome results
None listed